Thuy Pham, MD
Family Medicine · Los Angeles, CANPI 1023001864
Payments from drug & device makers
Across 42 payments — averaging $63.61 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$381
- AstraZeneca$375
- Lilly USA, LLC$369
- Novo Nordisk$169
- Bayer$169
- Merck$145
- plus $1K from 15 others
What the payments were for
- Food & beverage$2,672100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 4 | $381 |
| AstraZeneca | 3 | $375 |
| Lilly USA, LLC | 9 | $369 |
| Novo Nordisk | 3 | $169 |
| Bayer | 3 | $169 |
| Merck | 3 | $145 |
| Aimmune Therapeutics, Inc. | 1 | $125 |
| Kowa Pharmaceuticals America, Inc. | 1 | $122 |
| Gilead | 1 | $120 |
| Dexcom, Inc. | 1 | $120 |
| Boehringer Ingelheim | 1 | $113 |
| Exact Sciences | 1 | $100 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $100 |
| Scilex Pharmaceuticals Inc. | 1 | $65 |
| Kaleo, Inc. | 1 | $46 |
| Mannkind Corporation | 3 | $42 |
| AbbVie | 1 | $30 |
| Emergent Biosolutions Inc. | 1 | $23 |
| Pfizer | 1 | $21 |
| Dynavax Technologies Corporation | 1 | $20 |
| Cranial Technologies, Inc | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$2,672 in reported general payments places this provider in the 85th percentile of 10,533 family medicine providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| TrulicityDulaglutide | 90 | $102,193 |
| GenvoyaElviteg/Cob/Emtri/Tenof Alafen | 13 | $52,024 |
| EliquisApixaban | 53 | $41,171 |
| OzempicSemaglutide | 42 | $39,843 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 53 | $27,199 |
| JanuviaSitagliptin Phosphate | 29 | $25,509 |
| JardianceEmpagliflozin | 31 | $25,227 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 18 | $7,257 |
| Humulin 70/30 KwikpenInsulin Nph Hum/Reg Insulin Hm | 22 | $6,471 |
| Novolin 70-30 FlexpenInsulin Nph Hum/Reg Insulin Hm | 23 | $4,551 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 36 | $4,476 |
| Humulin 70-30Insulin Nph Hum/Reg Insulin Hm | 28 | $4,317 |
| Humulin N KwikpenInsulin Nph Human Isophane | 14 | $3,303 |
| Icosapent Ethyl | 20 | $3,207 |
| Atorvastatin Calcium | 331 | $2,428 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCTrulicity, Humulin 70-30, Humulin N | $369 | $108,496139 claims |
| GileadGenvoya | $120 | $52,02413 claims |
| PfizerEliquis | $21 | $41,17153 claims |
| Novo NordiskOzempic | $169 | $39,84342 claims |
| MerckJanuvia | $145 | $25,50929 claims |
| Boehringer IngelheimJardiance | $113 | $25,22731 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 10,533 family medicine providers in California.
Other family medicine in Los Angeles
- Albert NassirLos Angeles$5.7M
- Nader SobhLos Angeles$4.1M
- Alexander RivkinLos Angeles$2.8M
- Pamela KushnerLos Angeles$1.2M
- Scott HowellLos Angeles$793K
- Amina HaggagNorthridge$112.8M
- Steven ReynoldsLong Beach$53M
- Rizwana MohseniLake Forest$26.7M
- Daniel JohnsonSan Diego$15.7M
- Stacey LayleSan Diego$14.8M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.